MDS Pharma, Caprion, Gentris, MGH Partner to Form New Biomarker Alliance | GenomeWeb

MDS Pharma Services, Caprion Pharmaceuticals, Gentris, and Massachusetts General Hospital's department of radiology have teamed up to form a new Biomarker Alliance that offers clients proteomic, genomic, bioanalytic, and imaging technologies for developing biomarkers, the groups said last week.

Fred Pritchard, vice president of drug development programs at MDS Pharma Services, said that the idea behind the alliance is to enable clients to approach its members and discuss what might be the best one or two tools or techniques to apply to a particular question.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.